Based on these findings, combination therapy of CDK4/6 inhibitor palbociclib and MEK inhibitor PD0325901 was tested on KRAS-mutated CRC cells, BRAF-mutant CRC cells, normal colon epithelial cells, and CRC xenograft models to evaluate their efficacy and toxicity. Here, MAP2K7 is linked to colorectal carcinoma.